ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Industry-university collaboration Apollo licenses first product

by Michael McCoy
July 25, 2020 | APPEARED IN VOLUME 98, ISSUE 29

 

Apollo Therapeutics, a collaboration between three drug firms and tech transfer offices at three UK universities, has licensed its first product—a gene therapy developed at University College London—to the health-care investment firm Deerfield Management. Deerfield will further the research at its new laboratory in New York City. Apollo was formed in 2016 to translate academic research into medicines. Apollo CEO Richard Butt says he expects further licensing progress this year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment